Broad Institute - Articles and news items

Broad Institute Genomic Services offers genomic insight into Ninlaro

Industry news / 25 January 2016 / Victoria White

Ninlaro (ixazomib) was recently approved by the FDA, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+